The Trump administration has reached new drug pricing agreements with nine biotech and pharmaceutical companies, including BeiGene and Sun Pharmaceutical Co., Ltd. According to the agreement, these companies will provide outpatient drug discounts to state Medicaid programs, so that the prices paid by the states are consistent with the fees charged by participating pharmaceutical companies abroad. Participation in the state Medicaid program is voluntary. The announcement is the latest in a series of high-profile events held by the White House with pharmaceutical executives and President Donald Trump to highlight the affordability of healthcare ahead of the midterm elections. Trump said at a White House event on Monday that pharmaceutical companies “make most of their money in the US, which means they keep exploiting us. But it won't happen again.” Also participating in this agreement are UCB SA, Bridgebio Pharma Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Alcon, CSL Ltd., and Kyowa Kirin Co., Ltd.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.